Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics, Inc. ( LSTA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - Executive VP of R&D and Chief Medical Officer Conference Call Participants Lander Egaña-Gorroño Robert Sassoon - Water Tower Research LLC Peter Enderlin - MAZ Capital Advisors, LLC Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 6, 2025.

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities. Certepetide, Lisata's proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.

Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J.

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services throughout the world.  The clinical-stage pharmaceutical company said the award is in recognition of its unique therapeutic approach and focused clinical development plans, designed to produce products to address the unmet medical needs of patients with advanced solid tumors.

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it is the recipient of “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the effectiveness of antibody-drug conjugates (ADCs) in cancer treatment. The data, presented by Lisata's licensing partner Catalent at the 16th Annual World ADC San Diego Conference, showed that certepetide may improve tumor penetration and broaden the distribution of cytotoxic agents within tumors.

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata's licensing partner, Catalent, Inc. (“Catalent”), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025.

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m.

Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) -  Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D.

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Proactive: Hello, you're watching Proactive.

Deep Dive - Lisata Therapeutics Inc

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces its...

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) developed using Catalent's SMARTag technology platform.  The clinical-stage pharmaceutical company said Certepetide, a proprietary, internalizing RGD (arginyl-glycyl-aspartic acid), or “iRGD” cyclic peptide, is being tested by Lisata as a cancer therapeutic to be used in combination with other anti-cancer agents to enhance tumor targeting and penetration and improve treatment outcomes.

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases

Lisata Therapeutics Inc (NASDAQ:LSTA) announced what it called “encouraging” preliminary data from the pancreatic ductal adenocarcinoma (PDAC) cohort of the Phase 1/2a CENDIFOX trial.  The clinical-stage pharmaceutical company said the investigator-initiated trial is evaluating Lisata's proprietary investigational iRGD cyclic peptide product candidate, certepetide, in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers.

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions